For example, regorafenib was found to inhibit a distinct set of receptor kinases, including the vascular endothelial growth factor receptors (VEGFR1–3), TIE2, fibroblast growth factor receptor 1 (FGFR1), and platelet-derived growth factor receptor beta (PDGFR-b), and has been approved for treating hepatocellular carcinoma, colorectal cancer, and gastrointestinal stromal tumors [31,32,33,34]. The gene discussed is FGFR1; the disease is hepatocellular carcinoma.